Magna Scientia Advanced Biology and Pharmacy

eISSN: 2582-8363

Cross Ref DOI: 10.30574/msabp

Journal homepage: https://magnascientiapub.com/journals/msabp/

(Review Article)

Developing Integrated Genomic–Epidemiological Platforms to Improve Rapid Identification, Tracking, and Containment of Emerging Pathogens

Lucky David Mayaki *

School of Health Studies, Northern Illinois University, USA.

Magna Scientia Advanced Biology and Pharmacy, 2024, 11(01), 066-083

Publication history: Received on 30 November 2023; revised on 24 January 2024; accepted on 28 January 2024

Article DOI: https://doi.org/10.30574/msabp.2024.11.1.0007

Abstract

The accelerating emergence and re-emergence of infectious diseases has exposed critical limitations in traditional surveillance systems that operate in silos across genomics, epidemiology, and public health operations. Fragmented data flows, delayed reporting, and limited analytical integration have repeatedly constrained the ability of health systems to rapidly identify novel pathogens, trace transmission pathways, and implement timely containment strategies. Advances in high-throughput sequencing, digital epidemiology, and data analytics now present an opportunity to transform outbreak preparedness through integrated genomic–epidemiological platforms that unify molecular and population-level intelligence within a single operational framework. At a broad level, integrated platforms enable the continuous ingestion, harmonisation, and analysis of pathogen genomic data alongside epidemiological indicators such as case counts, mobility patterns, contact networks, and environmental signals. This convergence supports near real-time situational awareness, allowing public health authorities to detect anomalies earlier, distinguish between endemic circulation and emerging threats, and assess transmission dynamics with greater precision. Importantly, such systems enhance the capacity to monitor pathogen evolution, including the emergence of variants with altered transmissibility, virulence, or immune escape potential. Narrowing in focus, the development of integrated genomic–epidemiological platforms specifically strengthens rapid identification, tracking, and containment of emerging pathogens by linking sequence-derived insights directly to operational decision-making. Automated lineage assignment, phylogenetic clustering, and spatiotemporal modelling can be embedded within surveillance workflows to inform targeted testing, contact tracing, travel advisories, and resource allocation. When coupled with interoperable data governance, scalable infrastructure, and ethical safeguards, these platforms move beyond retrospective analysis toward proactive, intelligence-driven outbreak control. Ultimately, integrated genomic–epidemiological systems represent a foundational capability for resilient global health security in an era of accelerating biological risk.

Keywords: Genomic surveillance; Epidemiological integration; Emerging pathogens; Outbreak detection; Public health analytics; Disease containment

1. Introduction

1.1. Global Challenges in Emerging Pathogen Detection and Control

The global landscape of infectious disease control has become increasingly complex, shaped by rising outbreak frequency, accelerated human mobility, and intensifying ecological disruption [1]. Urbanisation, climate variability, deforestation, and intensified animal–human interfaces have expanded opportunities for zoonotic spillover, increasing the likelihood of novel and re-emerging pathogens [2]. At the same time, globalisation and dense transportation networks enable local outbreaks to propagate rapidly across borders, compressing response timelines and overwhelming public health systems [3].

* Corresponding author: Lucky David Mayaki

Despite advances in biomedical science, early detection of emerging pathogens remains uneven across regions. Many low- and middle-income countries face limited laboratory capacity, fragmented surveillance coverage, and insufficient real-time data sharing, constraining situational awareness during critical early stages of outbreaks [4]. Even in high-income settings, surveillance blind spots persist due to asymptomatic transmission, underreporting, and delayed healthcare engagement. These challenges are compounded by antimicrobial resistance and viral mutation dynamics, which further complicate containment strategies [5].

The COVID-19 pandemic exposed structural weaknesses in global preparedness, highlighting the consequences of delayed detection and fragmented response coordination. Outbreak control increasingly depends on the ability to identify transmission chains, track pathogen evolution, and anticipate epidemiological trends under conditions of uncertainty [6]. As emerging pathogens continue to challenge conventional public health tools, there is growing recognition that existing detection and control paradigms are insufficient for managing the speed, scale, and complexity of modern infectious disease threats [7].

1.2. Limitations of Traditional Epidemiological Surveillance Systems

Traditional epidemiological surveillance systems rely predominantly on clinical case reporting, laboratory confirmations, and periodic aggregation of population-level indicators. While these methods have underpinned public health practice for decades, they are inherently reactive and often characterised by significant reporting delays [3]. Time lags between infection, symptom onset, healthcare presentation, testing, and official notification limit the ability of authorities to intervene early in transmission cycles.

Data silos further constrain effectiveness. Surveillance datasets are frequently fragmented across healthcare providers, laboratories, public health agencies, and national jurisdictions, reducing interoperability and real-time visibility [8]. Inconsistent reporting standards, manual data entry, and variable diagnostic capacity introduce bias and incompleteness, particularly during surge conditions. As a result, outbreak signals may be detected only after widespread community transmission has already occurred.

Moreover, traditional systems tend to prioritise case counts over transmission dynamics, offering limited insight into pathogen evolution, superspreading events, or cryptic transmission pathways [5]. Predictive capacity is constrained by static analytical frameworks that struggle to incorporate heterogeneous data sources or adapt to rapidly changing epidemiological conditions. These limitations hinder proactive risk assessment and contribute to delayed, blunt public health responses. As outbreaks become more frequent and complex, reliance on conventional surveillance alone increasingly undermines the timeliness, precision, and effectiveness of disease control strategies [9].

1.3. Rationale for Integrated Genomic–Epidemiological Platforms

Integrated genomic–epidemiological platforms have emerged as a strategic response to the shortcomings of traditional surveillance systems, offering a pathway toward earlier detection and more targeted intervention. By combining pathogen genomic sequencing with epidemiological, clinical, and mobility data, these platforms enable high-resolution reconstruction of transmission networks and real-time monitoring of pathogen evolution [1]. Genomic data provide unique insights into mutation patterns, variant emergence, and transmission linkages that are invisible to case-based surveillance alone.

Integration enhances analytical depth by linking who is infected, where transmission occurs, and how pathogens spread over time [6]. This enables public health authorities to distinguish between local amplification and importation events, assess the effectiveness of control measures, and anticipate shifts in transmissibility or immune escape. When embedded within interoperable data infrastructures, integrated platforms support continuous surveillance rather than episodic reporting [4].

From a strategic perspective, integration is not merely a technical enhancement but a systemic necessity. Emerging pathogens operate across biological, social, and environmental domains, requiring surveillance architectures capable of synthesising diverse data streams [2]. Integrated platforms also support equity by enabling scalable, standardised surveillance across regions with varying resources. As global health threats intensify, genomic–epidemiological integration provides the conceptual and operational foundation for more anticipatory, adaptive, and resilient infectious disease surveillance systems, positioning data-driven intelligence at the core of outbreak preparedness and response [8].

2. From fragmented surveillance to integrated intelligence

2.1. Global Challenges in Emerging Pathogen Detection and Control

The global landscape of infectious disease control has become increasingly complex, shaped by rising outbreak frequency, accelerated human mobility, and intensifying ecological disruption [1]. Urbanisation, climate variability, deforestation, and intensified animal–human interfaces have expanded opportunities for zoonotic spillover, increasing the likelihood of novel and re-emerging pathogens [2]. At the same time, globalisation and dense transportation networks enable local outbreaks to propagate rapidly across borders, compressing response timelines and overwhelming public health systems [3].

Despite advances in biomedical science, early detection of emerging pathogens remains uneven across regions. Many low- and middle-income countries face limited laboratory capacity, fragmented surveillance coverage, and insufficient real-time data sharing, constraining situational awareness during critical early stages of outbreaks [4]. Even in high-income settings, surveillance blind spots persist due to asymptomatic transmission, underreporting, and delayed healthcare engagement. These challenges are compounded by antimicrobial resistance and viral mutation dynamics, which further complicate containment strategies [5].

The COVID-19 pandemic exposed structural weaknesses in global preparedness, highlighting the consequences of delayed detection and fragmented response coordination. Outbreak control increasingly depends on the ability to identify transmission chains, track pathogen evolution, and anticipate epidemiological trends under conditions of uncertainty [6]. As emerging pathogens continue to challenge conventional public health tools, there is growing recognition that existing detection and control paradigms are insufficient for managing the speed, scale, and complexity of modern infectious disease threats [7].

2.2. Limitations of Traditional Epidemiological Surveillance Systems

Traditional epidemiological surveillance systems rely predominantly on clinical case reporting, laboratory confirmations, and periodic aggregation of population-level indicators. While these methods have underpinned public health practice for decades, they are inherently reactive and often characterised by significant reporting delays [3]. Time lags between infection, symptom onset, healthcare presentation, testing, and official notification limit the ability of authorities to intervene early in transmission cycles.

Data silos further constrain effectiveness. Surveillance datasets are frequently fragmented across healthcare providers, laboratories, public health agencies, and national jurisdictions, reducing interoperability and real-time visibility [8]. Inconsistent reporting standards, manual data entry, and variable diagnostic capacity introduce bias and incompleteness, particularly during surge conditions. As a result, outbreak signals may be detected only after widespread community transmission has already occurred.

Moreover, traditional systems tend to prioritise case counts over transmission dynamics, offering limited insight into pathogen evolution, superspreading events, or cryptic transmission pathways [5]. Predictive capacity is constrained by static analytical frameworks that struggle to incorporate heterogeneous data sources or adapt to rapidly changing epidemiological conditions. These limitations hinder proactive risk assessment and contribute to delayed, blunt public health responses. As outbreaks become more frequent and complex, reliance on conventional surveillance alone increasingly undermines the timeliness, precision, and effectiveness of disease control strategies [9].

2.3. Rationale for Integrated Genomic–Epidemiological Platforms

Integrated genomic–epidemiological platforms have emerged as a strategic response to the shortcomings of traditional surveillance systems, offering a pathway toward earlier detection and more targeted intervention. By combining pathogen genomic sequencing with epidemiological, clinical, and mobility data, these platforms enable high-resolution reconstruction of transmission networks and real-time monitoring of pathogen evolution [1]. Genomic data provide unique insights into mutation patterns, variant emergence, and transmission linkages that are invisible to case-based surveillance alone.

Integration enhances analytical depth by linking who is infected, where transmission occurs, and how pathogens spread over time [6]. This enables public health authorities to distinguish between local amplification and importation events, assess the effectiveness of control measures, and anticipate shifts in transmissibility or immune escape. When embedded within interoperable data infrastructures, integrated platforms support continuous surveillance rather than episodic reporting [4].

From a strategic perspective, integration is not merely a technical enhancement but a systemic necessity. Emerging pathogens operate across biological, social, and environmental domains, requiring surveillance architectures capable of synthesising diverse data streams [2]. Integrated platforms also support equity by enabling scalable, standardised surveillance across regions with varying resources. As global health threats intensify, genomic–epidemiological integration provides the conceptual and operational foundation for more anticipatory, adaptive, and resilient infectious disease surveillance systems, positioning data-driven intelligence at the core of outbreak preparedness and response [8].

3. Conceptual foundations of genomic–epidemiological integration

3.1. Genomic Surveillance: Capabilities and Constraints

Genomic surveillance has become a critical component of modern infectious disease monitoring, enabling detailed characterisation of pathogen evolution and transmission dynamics. Through whole-genome sequencing, public health systems can identify mutations, classify variants, and reconstruct phylogenetic relationships between pathogen samples [7]. These capabilities support detection of emerging variants with altered transmissibility, virulence, or immune escape potential, providing insights that are unattainable through clinical surveillance alone.

Phylogenetic analysis allows inference of transmission linkages by comparing genetic similarity across samples, offering powerful tools for outbreak investigation and source attribution [9]. In near real time, sequencing data can reveal whether cases arise from local transmission chains or repeated importation events. This molecular resolution is particularly valuable for monitoring rapidly evolving RNA viruses and tracking antimicrobial resistance patterns [11].

However, genomic surveillance exhibits important constraints when deployed in isolation. Sequencing coverage is often uneven, biased toward symptomatic cases or regions with advanced laboratory capacity, limiting representativeness [13]. Turnaround times may lag behind epidemiological developments, especially during surge conditions. Most critically, genomic data alone lacks contextual information about host behaviour, exposure settings, and population dynamics. Without epidemiological linkage, phylogenetic clusters may be misinterpreted or overgeneralised.

Additionally, identical or near-identical sequences do not necessarily imply direct transmission, particularly in high-prevalence settings [15]. Conversely, epidemiologically linked cases may appear genetically distinct due to sampling gaps. These limitations underscore that while genomic surveillance offers unprecedented molecular insight, its standalone application risks producing parallel but incomplete intelligence. Its full value emerges only when embedded within broader epidemiological frameworks that contextualise genetic signals within real-world transmission environments [8].

3.2. Epidemiological Data Streams and Population-Level Intelligence

Epidemiological surveillance provides population-level intelligence essential for understanding disease burden, transmission patterns, and intervention effectiveness. Core data streams include case notifications, hospital admissions, mortality records, and laboratory test results, which collectively describe temporal and spatial trends in infection [10]. Contact tracing data further enrich this picture by identifying exposure networks and high-risk settings, supporting targeted containment strategies.

Beyond traditional surveillance, syndromic data sources such as emergency department visits, pharmacy sales, and absenteeism reports offer early indicators of emerging outbreaks before laboratory confirmation is widespread [7]. Mobility data derived from transportation systems or digital platforms provide insight into population movement, informing assessments of spatial spread and importation risk [12]. Environmental surveillance, including wastewater monitoring and vector sampling, adds another layer by detecting pathogen presence independent of healthcare-seeking behaviour.

Despite their breadth, epidemiological data streams face persistent challenges. Reporting delays, under-ascertainment, and inconsistent case definitions reduce timeliness and comparability [14]. Data are frequently siloed across institutions and jurisdictions, limiting interoperability and comprehensive analysis. Moreover, traditional epidemiological indicators often struggle to distinguish between coincident outbreaks, superspreading events, and sustained community transmission.

Analytical approaches applied to these datasets are commonly descriptive and retrospective, constraining predictive capacity [9]. While epidemiological surveillance excels at capturing population-level patterns, it provides limited insight into pathogen evolution and micro-level transmission pathways. These constraints highlight the complementary but incomplete nature of epidemiological intelligence when decoupled from molecular data, reinforcing the need for integrated analytical architectures that bridge biological and population perspectives [15].

3.3. The Integration Imperative: Linking Molecular and Population Data



Figure 1 Conceptual Framework for Integrated Genomic–Epidemiological Surveillance

Integrating genomic and epidemiological data transforms surveillance from parallel information streams into actionable intelligence. Molecular data elucidate how pathogens evolve and relate genetically, while epidemiological data explain where, when, and among whom transmission occurs [8]. When linked, these dimensions enable high-resolution reconstruction of transmission networks that neither approach can achieve independently.

Integration allows genomic clusters to be interpreted within temporal, spatial, and behavioural contexts, reducing misclassification of transmission events [11]. For example, combining phylogenetic analysis with contact tracing can distinguish true outbreak clusters from coincidental genetic similarity in high-incidence settings. Similarly, mobility and exposure data contextualise variant spread, supporting early identification of geographic expansion or superspreading nodes [13].

From an operational perspective, integrated platforms enhance decision-making speed and precision. Public health authorities can prioritise interventions based on combined signals of genetic novelty, epidemiological growth rates, and population vulnerability [7]. This supports targeted testing, adaptive vaccination strategies, and proportional non-pharmaceutical interventions rather than blanket responses.

Integration also improves predictive capability. By embedding genomic indicators into epidemiological models, analysts can anticipate shifts in transmissibility or immune escape before they manifest in case counts [14]. Over time, integrated datasets enable learning systems that refine risk assessment based on historical associations between molecular changes and epidemiological outcomes.

Crucially, integration shifts surveillance from reactive reporting toward anticipatory intelligence. Rather than asking whether cases are rising, integrated systems address why transmission is occurring and how it may evolve [10]. As illustrated in Figure 1, the conceptual framework for integrated genomic–epidemiological surveillance positions data linkage as the central mechanism through which biological insight and population intelligence converge. This integration imperative reflects a strategic evolution in outbreak detection and control, aligning surveillance architectures with the complexity, speed, and uncertainty of contemporary infectious disease threats [15].

4. Data architecture and interoperability for integrated platforms

4.1. Data Sources, Modalities, and Ingestion Pipelines

Integrated genomic–epidemiological platforms rely on the coordinated ingestion of heterogeneous data modalities that operate at different temporal, spatial, and biological resolutions. At the molecular level, whole-genome and partial-genome sequences generated from clinical and environmental samples form the primary genomic input, accompanied by essential metadata such as sampling date, location, sequencing technology, and quality metrics [13]. Without this contextual metadata, genomic sequences have limited analytical value for transmission inference or variant tracking.

Clinical data represent a second critical modality, encompassing laboratory test results, symptom onset dates, disease severity indicators, vaccination status, and outcomes such as hospitalisation or mortality [15]. These records link molecular signals to clinical phenotypes, enabling assessment of virulence, immune escape, and treatment effectiveness. Population-level data further extend analytical scope through mobility indicators, contact tracing records, syndromic surveillance feeds, and environmental monitoring such as wastewater sampling [18].

The ingestion of these diverse data streams requires robust, scalable architectures capable of handling variable data velocity and volume. Real-time or near–real-time pipelines increasingly rely on automated application programming interfaces, secure data exchanges, and event-driven architectures that minimise manual intervention and reporting delays [20]. Batch ingestion remains relevant for legacy systems and retrospective analyses but introduces latency that limits early warning capability.

Crucially, ingestion pipelines must preserve data provenance and versioning to ensure analytical reproducibility. As platforms mature, ingestion design shifts from simple data collection toward continuous data integration, enabling iterative model updates and adaptive surveillance. The effectiveness of integrated platforms therefore depends not only on the richness of data sources but on the reliability, timeliness, and traceability of ingestion processes that transform raw inputs into analytically usable streams [22].

4.2. Interoperability, Standards, and Data Harmonisation

The analytical power of integrated surveillance platforms is fundamentally constrained by interoperability. Genomic, clinical, and epidemiological datasets are typically generated by disparate institutions using different formats, terminologies, and reporting conventions [14]. Without harmonisation, integration efforts risk producing fragmented systems that replicate existing silos rather than dissolving them.

Standards provide the foundation for interoperability. In genomics, standardised sequence formats, metadata schemas, and quality thresholds enable cross-laboratory comparison and large-scale phylogenetic analysis [17]. Clinical and epidemiological domains similarly rely on common case definitions, coding systems, and temporal conventions to support aggregation and comparative analysis across jurisdictions. Ontologies play a critical role by mapping semantically equivalent concepts across datasets, allowing machine-readable alignment of variables such as symptoms, exposure settings, or intervention types.

Cross-jurisdictional compatibility presents additional challenges. Legal, institutional, and infrastructural differences shape how data are collected and shared, leading to uneven granularity and completeness [19]. Harmonisation strategies therefore extend beyond technical standards to include alignment of reporting frequencies, minimum data requirements, and quality benchmarks. Middleware layers and data transformation services are increasingly used to translate heterogeneous inputs into unified analytical models without requiring full upstream standardisation.

Importantly, harmonisation is not a one-time exercise. As pathogens evolve and surveillance priorities shift, data models must adapt while preserving backward compatibility [21]. Flexible schema design and modular data architectures enable platforms to incorporate new indicators without disrupting existing workflows. Effective interoperability thus reflects an ongoing system-design commitment, ensuring that integrated platforms remain scalable, comparable, and analytically coherent across time, geography, and institutional boundaries [13].

4.3. Data Governance, Privacy, and Ethical Safeguards

Table 1 Core Data Types, Sources, and Analytical Roles in Integrated Genomic–Epidemiological Platforms

Data Type	Primary Sources	Key Attributes	Analytical Role in Integrated Platforms
Genomic sequence data	Clinical laboratories, public health reference labs, environmental sampling (e.g., wastewater)	Whole or partial genomes, mutation profiles, sequence quality metrics	Variant detection, lineage assignment, phylogenetic reconstruction, evolutionary rate estimation
Genomic metadata	Sequencing laboratories, surveillance registries	Sampling date, location, specimen type, sequencing platform	Temporal and spatial contextualisation of sequences, correction for sampling bias
Clinical records	Hospitals, primary care systems, laboratory information systems	Symptoms, severity, comorbidities, vaccination status, outcomes	Linking variants to clinical impact, severity assessment, risk stratification
Case surveillance data	National and subnational public health agencies	Case counts, onset dates, demographic variables	Estimation of incidence, reproduction numbers, epidemic growth rates
Contact tracing data	Public health authorities, digital tracing systems	Exposure networks, contact timing, setting information	Reconstruction of transmission chains, identification of superspreading events
Syndromic surveillance data	Emergency departments, pharmacies, absenteeism systems	Pre-diagnostic health indicators, symptom clusters	Early outbreak detection, triangulation with confirmed case trends
Mobility data	Transport authorities, aggregated mobile device datasets	Movement flows, travel volumes, spatial connectivity	Modelling spatial spread, importation risk, intervention targeting
Environmental surveillance data	Wastewater facilities, vector monitoring programmes	Pathogen presence, concentration trends	Detection of cryptic transmission independent of healthcare utilisation
Intervention and policy data	Government agencies, health authorities	Timing and type of control measures	Evaluation of intervention effectiveness, causal inference
Health system capacity data	Hospitals, emergency management agencies	Bed capacity, staffing levels, resource utilisation	Anticipating healthcare strain, informing surge planning
Demographic and socioeconomic data	Census agencies, statistical offices	Population density, age structure, deprivation indices	Equity analysis, vulnerability mapping, prioritisation of interventions
Financial and logistical data	Public health budgets, supply-chain systems	Resource availability, procurement timelines	Operational planning, allocation efficiency, response feasibility

As integrated platforms expand data linkage and analytical reach, governance, privacy, and ethical considerations become central to system legitimacy and sustainability. Genomic data, when combined with clinical and location information, raise heightened risks of re-identification and misuse, even when traditional identifiers are removed [16]. Robust governance frameworks are therefore required to define permissible uses, access controls, and accountability mechanisms.

Consent models must balance public health imperatives with individual rights. In emergency contexts, broad public interest justifications may support data use without explicit consent, but long-term surveillance requires transparent policies that articulate how data are collected, stored, and repurposed [18]. Anonymisation and pseudonymisation techniques reduce privacy risk but are not absolute safeguards, particularly when datasets are richly linked across domains.

Equity considerations further shape governance design. Surveillance systems that disproportionately represent well-resourced regions or populations risk reinforcing existing health disparities [20]. Ethical platforms must therefore promote inclusive data collection, capacity building, and fair benefit sharing, ensuring that insights generated from integrated data translate into public health gains across diverse communities.

Trust is the enabling condition for sustained data sharing. Clear governance structures, independent oversight, and auditable decision processes enhance public and institutional confidence [22]. Transparency regarding analytical methods, data limitations, and uncertainty is essential to prevent misinterpretation or politicisation of surveillance outputs.

Ultimately, governance is not an external constraint but an integral component of analytical effectiveness. Platforms that neglect privacy and ethics risk data withdrawal, legal challenge, and erosion of public trust, undermining surveillance objectives. By embedding governance, privacy protection, and ethical safeguards alongside interoperability and technical design, integrated genomic–epidemiological platforms can sustain both analytical power and social legitimacy in the long term [19].

5. Analytical methods for identification and tracking of emerging pathogens

5.1. Variant Detection and Phylogenetic Analysis

Variant detection and phylogenetic analysis form the analytical core of genomic surveillance, enabling systematic tracking of pathogen evolution over time. Lineage assignment algorithms classify pathogen sequences into phylogenetic groups based on shared mutation patterns, supporting the identification of emerging variants and their global or regional spread [18]. This process relies on continuously updated reference trees and nomenclature systems that reflect evolutionary divergence as new sequences are deposited.

Mutation tracking extends beyond lineage labels to examine specific genetic changes associated with altered transmissibility, virulence, or immune escape. By monitoring the accumulation and co-occurrence of mutations, analysts can identify convergent evolution and selection pressures acting on the pathogen population [20]. These insights are critical for anticipating changes in epidemiological behaviour before they are evident in case or hospitalisation data.

Phylogenetic inference reconstructs evolutionary relationships by estimating ancestral lineages and branching patterns among sampled sequences. Time-calibrated phylogenies incorporate sampling dates to infer rates of evolution and approximate transmission timelines [22]. Such analyses support hypotheses about introduction events, diversification speed, and the relative contribution of local transmission versus importation.

However, phylogenetic conclusions are probabilistic rather than deterministic. Sampling bias, uneven sequencing coverage, and recombination events can distort tree topology and branch lengths [19]. Analytical robustness therefore depends on transparent uncertainty quantification and sensitivity testing across alternative models. When interpreted cautiously, phylogenetic analysis provides a powerful molecular framework that, when integrated with epidemiological data, enables deeper insight into how and why variants emerge, persist, or decline within populations [25].

5.2. Spatiotemporal Epidemiological Modelling

Spatiotemporal epidemiological modelling translates surveillance data into structured representations of disease spread across populations and geographies. These models characterise transmission dynamics by integrating case counts, onset dates, demographic attributes, and spatial information to estimate key parameters such as reproduction numbers, generation intervals, and growth rates [18]. When applied longitudinally, they reveal how transmission intensity evolves in response to interventions or behavioural change.

Spatial components capture heterogeneity in risk across regions, enabling identification of hotspots, corridors of spread, and areas of persistent transmission [21]. Coupled with mobility and contact data, spatiotemporal models assess how population movement influences dissemination patterns, informing border controls or targeted mitigation strategies. Forecasting frameworks extend these analyses by projecting future incidence under alternative scenarios, supporting anticipatory decision-making rather than reactive response.

The integration of genomic data enhances spatiotemporal models by constraining assumptions about transmission linkage and timing [23]. Variant-specific growth rates can be estimated by combining lineage frequency data with epidemiological trends, enabling early detection of competitive advantages. This linkage improves attribution of observed case increases to biological change rather than behavioural or reporting artefacts.

Despite their utility, spatiotemporal models face limitations related to data quality, parameter uncertainty, and structural assumptions [20]. Forecast accuracy declines as projection horizons extend or as behavioural responses shift unpredictably. Transparent communication of uncertainty and regular model updating are therefore essential.

By embedding genomic insights into spatiotemporal epidemiological frameworks, integrated platforms move beyond descriptive mapping toward mechanistic understanding of population spread. This synthesis strengthens situational awareness and supports proportionate, evidence-based public health action under dynamic conditions [25].

5.3. Linking Genomic Signals to Transmission Chains

Linking genomic signals to transmission chains represents a critical advance in outbreak investigation and control. While phylogenetic clustering suggests genetic relatedness, integration with epidemiological data is required to resolve who infected whom, where transmission occurred, and over what time frame [19]. Combined analysis reduces ambiguity inherent in molecular or epidemiological inference alone.

By aligning sequence similarity with contact tracing, exposure histories, and temporal proximity, integrated approaches distinguish true transmission clusters from coincidental genetic resemblance in high-incidence settings [22]. This is particularly important for identifying superspreading events, where a single individual or setting contributes disproportionately to onward transmission. Genomic confirmation strengthens attribution and guides targeted interventions.

Integrated analysis also uncovers cryptic transmission chains that evade traditional surveillance, such as asymptomatic spread or transmission in marginalised populations with limited healthcare engagement [24]. In these contexts, genomic divergence patterns can signal undetected circulation even when reported case numbers appear stable.

However, resolution remains probabilistic. Incomplete sampling, reporting delays, and recall bias constrain reconstruction accuracy [18]. Analytical frameworks therefore emphasise likelihood-based inference rather than definitive assignment. When communicated appropriately, these insights support prioritisation rather than blame attribution.

Linking genomic and epidemiological signals thus transforms outbreak response from coarse containment toward precise disruption of transmission pathways. This capability enhances efficiency, reduces unnecessary restrictions, and improves equity by focusing resources where they are most likely to interrupt ongoing spread [25].

5.4. Early Warning Systems and Anomaly Detection

Early warning systems represent the forward-looking application of integrated surveillance analytics, shifting emphasis from retrospective explanation to proactive detection. By continuously monitoring genomic, epidemiological, and contextual indicators, anomaly detection algorithms identify deviations from expected patterns that may signal emerging threats [21]. These anomalies may include sudden increases in variant frequency, unexplained transmission clusters, or atypical spatial spread.

Statistical process control methods, Bayesian change-point detection, and machine learning techniques are increasingly applied to high-dimensional surveillance data to flag early signals under uncertainty [23]. Integration enhances sensitivity by requiring concordant anomalies across molecular and population domains, reducing false positives associated with noisy single-source indicators.



Figure 2 Analytical Workflow for Integrated Detection and Transmission Tracking

Timeliness is critical. Automated alerting mechanisms embedded within analytical pipelines enable rapid escalation to public health authorities, shortening the interval between emergence and response [18]. Importantly, alerts are probabilistic assessments rather than definitive diagnoses, necessitating expert review and contextual interpretation.

Ethical considerations shape early warning design. Systems must balance sensitivity with proportionality to avoid unnecessary alarm or stigmatisation of communities [24]. Transparent thresholds, governance oversight, and clear communication protocols are essential for maintaining trust.

By operationalising integrated analytics into early warning functions, surveillance platforms support anticipatory governance of infectious disease risk. This evolution positions data-driven intelligence as an active component of preparedness, enabling earlier, more targeted, and more effective interventions in the face of rapidly evolving pathogen threats [25].

6. Operationalisation for rapid containment and public health action

6.1. Translating Analytics into Public Health Decisions

The value of integrated genomic–epidemiological analytics ultimately depends on their translation into timely and proportionate public health decisions. Analytical outputs must therefore be explicitly aligned with policy triggers, operational thresholds, and decision mandates rather than remaining abstract indicators of risk [26]. Variant growth rates, reproduction number estimates, and phylogenetic clustering metrics become actionable only when mapped to predefined response options such as enhanced surveillance, targeted testing, or escalation of control measures.

Decision relevance requires calibration. Thresholds for action must balance sensitivity to emerging threats with tolerance for uncertainty, avoiding both delayed response and unnecessary intervention [28]. Integrated platforms support this calibration by combining molecular signals with epidemiological trends, enabling decision-makers to distinguish biological change from artefacts of testing intensity or reporting delay. For example, a rising variant frequency accompanied by stable case counts may warrant monitoring, while concurrent increases across both domains may justify immediate action.

Operationalisation also depends on interpretability. Public health leaders require clear summaries, confidence bounds, and scenario implications rather than raw analytical complexity [30]. Dashboards and decision briefs translate high-dimensional outputs into policy-relevant narratives, supporting rapid situational assessment during time-constrained deliberations. Importantly, analytics should inform graded responses rather than binary decisions, enabling proportionality in intervention design.

Institutional context further shapes translation. Legal authorities, governance norms, and political considerations influence how analytical evidence is weighed and acted upon [27]. Integrated platforms do not replace judgement but enhance it by grounding decisions in convergent evidence streams. When effectively embedded into decision processes, integrated analytics shorten the gap between detection and response, improving the timeliness, precision, and legitimacy of public health action under conditions of uncertainty [32].

6.2. Targeted Interventions Enabled by Integrated Platforms

Integrated genomic–epidemiological platforms enable a shift from population-wide measures toward targeted interventions tailored to specific transmission dynamics. By resolving where, how, and among whom transmission is occurring, these platforms support more efficient allocation of public health resources [26]. Testing strategies can be adapted based on variant prevalence, transmission intensity, and population vulnerability, prioritising high-risk settings rather than relying on uniform testing expansion.

Contact tracing benefits particularly from integration. Genomic confirmation of transmission clusters allows prioritisation of tracing efforts toward networks most likely to sustain onward spread [29]. This reduces the burden on tracing systems during surges while improving effectiveness. Similarly, identification of superspreading events or settings enables rapid deployment of focused interventions such as temporary closures, enhanced ventilation, or targeted vaccination campaigns.

Resource allocation decisions are also strengthened. Integrated analytics inform where to deploy laboratory capacity, mobile testing units, or clinical surge resources based on combined signals of epidemiological growth and variant-associated severity [31]. In vaccination programmes, integration supports adaptive strategies that account for immune escape risk, enabling prioritisation of booster campaigns in affected regions or populations.

Crucially, targeted interventions improve equity as well as efficiency. Rather than imposing broad restrictions that disproportionately affect vulnerable groups, integrated insights support interventions proportional to demonstrated risk [27]. However, precision must be balanced with fairness and transparency to avoid stigmatisation or exclusion. When governed appropriately, integrated platforms enable public health systems to intervene earlier, more precisely, and with fewer unintended social and economic consequences than blunt, population-wide measures [32].

6.3. Cross-Agency Coordination and Decision Support Systems

Effective use of integrated analytics requires coordination across agencies responsible for surveillance, healthcare delivery, emergency management, and policy implementation. Genomic–epidemiological insights often span institutional boundaries, necessitating shared situational awareness and aligned decision-making [28]. Decision support systems serve as the connective infrastructure that translates analytics into coordinated action.

These systems integrate data visualisation, scenario analysis, and alerting functions into shared platforms accessible to authorised stakeholders. Common operating pictures reduce information asymmetry between agencies, supporting coherent responses across national, regional, and local levels [30]. For example, alignment between public health authorities and healthcare providers enables early mobilisation of hospital capacity in response to variant-associated severity signals.

Governance arrangements underpin coordination. Clear roles, escalation pathways, and decision rights are required to prevent analytical insights from becoming stalled by institutional fragmentation [26]. Memoranda of understanding and data-sharing agreements formalise collaboration, while joint analytical units foster trust and shared interpretation of evidence.

Communication is equally critical. Integrated platforms support consistent messaging by providing a common evidentiary base for public communication, reducing confusion and conflicting guidance [31]. Transparency regarding uncertainty and rationale enhances credibility, particularly during rapidly evolving situations.

As surveillance becomes more data-intensive and analytically sophisticated, decision support systems evolve from passive reporting tools into active coordination mechanisms. By embedding integrated analytics into governance and communication infrastructures, public health systems can respond with greater coherence, speed, and accountability across complex institutional landscapes [32].

6.4. Feedback Loops and Adaptive Response Mechanisms

Integrated platforms enable continuous learning through feedback loops that connect interventions back to analytical models. As policies are implemented, new data on transmission, variant prevalence, and behavioural response are ingested, allowing models to be recalibrated in near real time [29]. This adaptive cycle improves forecast accuracy and refines understanding of intervention effectiveness.

Feedback mechanisms support mid-course correction. Interventions that fail to reduce transmission can be adjusted or withdrawn, while successful strategies are reinforced [27]. Over time, accumulated evidence strengthens institutional memory, informing future outbreak responses.

Crucially, adaptive response mechanisms reduce reliance on static assumptions embedded at the outset of crises. By operationalising learning as a core system function, integrated genomic–epidemiological platforms support resilient public health governance capable of evolving alongside pathogen dynamics and societal response [32].

Table 2 Public Health Decisions Supported by Integrated Genomic–Epidemiological Insights

Decision Domain	Integrated Data Inputs	Analytical Insight Generated	Public Health Action Enabled
Variant monitoring and classification	Genomic sequences, phylogenetic trees, case surveillance	Detection of emerging variants, growth advantage estimation	Escalation of surveillance, variant designation, risk communication
Testing strategy design	Case trends, variant prevalence, syndromic indicators	Identification of high-risk populations and settings	Targeted testing expansion, adaptive testing criteria
Contact tracing prioritisation	Genomic clusters, contact networks, exposure timelines	Differentiation of true transmission clusters	Focused tracing, rapid disruption of active chains
Outbreak investigation	Genomic similarity, temporal and spatial case linkage	Source attribution and transmission pathway reconstruction	Targeted containment, setting-specific interventions
Vaccination and booster deployment	Variant immune escape signals, demographic risk data	Assessment of population-level susceptibility	Prioritised vaccination or booster campaigns
Non-pharmaceutical intervention calibration	Reproduction number estimates, mobility data, variant growth	Evaluation of transmission drivers	Proportional restrictions, targeted mitigation measures
Healthcare surge planning	Case forecasts, severity-linked variant data	Anticipation of healthcare demand	Pre-positioning of beds, staff, and supplies
Border and travel risk management	Variant geography, mobility flows, importation analysis	Assessment of cross-border transmission risk	Testing, screening, or quarantine policy adjustments
Risk communication and public messaging	Integrated trend analysis, uncertainty estimates	Coherent situational awareness	Consistent guidance, transparent public updates
Policy escalation and de-escalation	Multi-domain indicators, trend convergence	Evidence-based threshold assessment	Timely activation or relaxation of measures
Equity-focused intervention planning	Socioeconomic data, access indicators, transmission patterns	Identification of vulnerable communities	Targeted outreach, resource redistribution
International coordination	Shared genomic and epidemiological intelligence	Early warning of global spread	Coordinated response, information sharing

7. Scalability, resilience, and global deployment considerations

7.1. Infrastructure Scalability Across Resource Settings

The scalability of integrated genomic–epidemiological platforms is central to their global relevance, particularly given wide disparities in technical capacity across low-, middle-, and high-income settings. In resource-constrained contexts, limitations in laboratory infrastructure, digital connectivity, and skilled workforce availability constrain routine genomic sequencing and real-time analytics [30]. Scalable architectures must therefore support modular deployment, enabling countries to adopt core surveillance functions while progressively expanding analytical sophistication as capacity grows.

Cloud-based infrastructures and shared analytical services offer practical pathways for scalability by reducing upfront capital requirements and enabling access to advanced computational resources [32]. Tiered system designs allow basic data ingestion and reporting to operate independently of high-throughput sequencing or advanced modelling components. Regional sequencing hubs and pooled procurement mechanisms further support scalability by distributing costs and expertise across multiple jurisdictions [33].

In higher-income settings, scalability challenges differ, often relating to system integration rather than basic capacity. Legacy information systems, fragmented governance, and data silos can impede the scaling of integrated platforms across agencies or regions [31]. Interoperable architectures and common standards are therefore essential to ensure that increased data volume translates into analytical value rather than operational complexity.

Critically, scalability is not solely a technical challenge. Sustainable financing, workforce development, and institutional ownership shape long-term viability [35]. Platforms that are adaptable to diverse resource environments enhance equity by ensuring that early detection and actionable intelligence are not confined to a small subset of well-resourced countries, strengthening global preparedness as a collective good.

7.2. System Resilience, Timeliness, and Reliability Under Crisis Conditions

Integrated surveillance platforms must remain resilient under crisis conditions characterised by surging data volumes, workforce strain, and infrastructure stress. During outbreaks, system performance is tested by sudden increases in sequencing demand, reporting frequency, and analytical urgency [31]. Architectures that rely heavily on manual processes or single points of failure are particularly vulnerable to disruption.

Resilience is achieved through redundancy, automation, and elastic computing capacity that can scale rapidly in response to demand spikes [34]. Real-time ingestion pipelines and automated quality checks reduce data latency, preserving the value of early warning signals. Continuity planning, including backup systems and distributed access, ensures that surveillance functions persist even when local infrastructure is compromised.

Timeliness and reliability are inseparable from trust. Delayed or inconsistent outputs undermine confidence in analytical guidance and weaken compliance with public health recommendations [30]. Designing platforms that prioritise robustness under stress therefore strengthens both operational effectiveness and institutional credibility during emergencies [35].

7.3. International Collaboration and Data Sharing Ecosystems

Emerging pathogen threats transcend national boundaries, making international collaboration a prerequisite for effective surveillance. Integrated genomic–epidemiological platforms contribute to global health security by enabling timely sharing of sequence data, epidemiological indicators, and analytical insights across countries [32]. Such collaboration supports early detection of cross-border transmission and coordinated response to variants of concern.

Data sharing ecosystems depend on trust, reciprocity, and clear governance frameworks. Unequal access to analytical benefits or concerns over data misuse can deter participation, particularly for lower-resource countries [33]. Equitable sharing arrangements, capacity-building partnerships, and recognition of data contributors strengthen collective engagement.

Global interoperability standards and federated data models allow countries to retain data sovereignty while contributing to shared situational awareness [34]. By embedding collaboration into platform design, integrated surveillance systems move beyond national tools toward components of a coordinated global architecture, enhancing collective resilience against future infectious disease threats [35].



Figure 3 Scalable Architecture for National and Transnational Genomic–Epidemiological Platforms

8. Conclusion, Future directions and strategic implications for global health security

8.1. From Reactive Surveillance to Predictive Preparedness

This article has traced a clear evolution from fragmented, reactive surveillance systems toward integrated, data-driven architectures capable of supporting predictive preparedness. Traditional surveillance approaches, while foundational, are inherently retrospective, often detecting outbreaks only after transmission is well established. By contrast, integrated genomic–epidemiological platforms enable earlier situational awareness by synthesising molecular evolution, population dynamics, and contextual signals into coherent analytical intelligence.

The integration of genomic and epidemiological data transforms surveillance from a reporting function into a learning system. Rather than asking whether an outbreak is occurring, integrated platforms address how transmission is unfolding, why certain variants or settings drive spread, and where interventions can be most effective. This shift enables anticipation rather than reaction, allowing public health systems to intervene earlier, more precisely, and with greater proportionality.

Predictive preparedness does not imply certainty. Instead, it reflects an institutional capacity to operate under uncertainty using convergent evidence, adaptive models, and continuous feedback. Integrated platforms support this capacity by shortening detection-to-decision timelines, revealing hidden transmission pathways, and enabling scenario-based planning. As emerging pathogen threats increase in frequency and complexity, preparedness increasingly depends on systems that evolve alongside biological and social dynamics. Integrated surveillance thus represents not merely a technological upgrade, but a fundamental reorientation of public health intelligence toward foresight, resilience, and strategic adaptability.

8.2. Policy, Investment, and Research Priorities

Realising the full potential of integrated genomic–epidemiological platforms requires sustained commitment across policy, investment, and research domains. For governments, the priority lies in embedding integrated surveillance within core public health mandates rather than treating it as an ad hoc or crisis-specific capability. This includes long-term funding, workforce development, and governance frameworks that support continuous operation, data sharing, and ethical oversight.

Investment strategies must prioritise scalability and equity. Infrastructure design should accommodate diverse resource settings, ensuring that analytical benefits are not concentrated solely in high-income contexts. Regional hubs, shared services, and federated models offer pathways to broaden access while respecting national sovereignty. Importantly, investment decisions should recognise surveillance as a form of critical infrastructure, analogous to healthcare delivery systems or emergency response capacity.

For the scientific community, integrated platforms open new research frontiers at the intersection of genomics, epidemiology, data science, and social science. Methodological innovation is needed to improve inference under uncertainty, address bias and representativeness, and translate complex analytics into actionable guidance. Equally important is research on governance, ethics, and trust, recognising that technical capability alone is insufficient without societal legitimacy.

Together, aligned policy, sustained investment, and interdisciplinary research can consolidate integrated surveillance as a cornerstone of modern public health, strengthening global readiness for the infectious disease challenges ahead.

Compliance with ethical standards

Disclosure of conflict of interest

No conflict of interest to be disclosed.

References

[1] Gardy JL, Loman NJ. Towards a genomics-informed, real-time, global pathogen surveillance system. Nature Reviews Genetics. 2018 Jan;19(1):9-20.

[2] Tang P, Croxen MA, Hasan MR, Hsiao WW, Hoang LM. Infection control in the new age of genomic epidemiology. American journal of infection control. 2017 Feb 1;45(2):170-9.

[3] Tang P, Croxen MA, Hasan MR, Hsiao WW, Hoang LM. Infection control in the new age of genomic epidemiology. American journal of infection control. 2017 Feb 1;45(2):170-9.

[4] Solarin A, Chukwunweike J. Dynamic reliability-centered maintenance modeling integrating failure mode analysis and Bayesian decision theoretic approaches. *International Journal of Science and Research Archive*. 2023 Mar;8(1):136. doi:10.30574/ijsra.2023.8.1.0136.

[5] Pollett S, Fauver JR, Maljkovic Berry I, Melendrez M, Morrison A, Gillis LD, Johansson MA, Jarman RG, Grubaugh ND. Genomic epidemiology as a public health tool to combat mosquito-borne virus outbreaks. The Journal of infectious diseases. 2020 Mar 28;221(Supplement_3):S308-18.

[6] Eze Dan-Ekeh. DEVELOPING ENTERPRISE-SCALE MARKET EXPANSION STRATEGIES COMBINING TECHNICAL PROBLEM-SOLVING AND EXECUTIVE-LEVEL NEGOTIATIONS TO SECURE TRANSFORMATIVE INTERNATIONAL ENERGY PARTNERSHIPS. International Journal Of Engineering Technology Research & Management (IJETRM). 2018Dec21;02(12):165–77.

[7] Bianconi I, Aschbacher R, Pagani E. Current uses and future perspectives of genomic technologies in clinical microbiology. Antibiotics. 2023 Oct 30;12(11):1580.

[8] Daniel Akanbi. Transforming multinational supply networks using predictive modeling, supplier-risk intelligence, and synchronized logistics planning to reduce volatility and strengthen operational continuity. Int J Finance Manage Econ 2022;5(1):157-166. DOI: 10.33545/26179210.2022.v5.i1.680

[9] Rasmussen AL, Katze MG. Genomic signatures of emerging viruses: a new era of systems epidemiology. Cell Host & Microbe. 2016 May 11;19(5):611-8.

[10] Hill V, Githinji G, Vogels CB, Bento AI, Chaguza C, Carrington CV, Grubaugh ND. Toward a global virus genomic surveillance network. Cell Host & Microbe. 2023 Jun 14;31(6):861-73.

[11] Olofintuyi D, Osinlu V, Odedeji A, Oluwadele G. Toxicological profiles of African medicinal plants used in trypanosomiasis therapy: mechanisms, safety, and knowledge gaps. *GSC Biological and Pharmaceutical Sciences*. 2018;5(3):192–205. doi:10.30574/gscbps.2018.5.3.0170

[12] Oboh MA, Omoleke SA, Ajibola O, Manneh J, Kanteh A, Sesay AK, Amambua-Ngwa A. Translation of genomic epidemiology of infectious pathogens: Enhancing African genomics hubs for outbreaks. International Journal of Infectious Diseases. 2020 Oct 1;99:449-51.

[13] Pronyk PM, de Alwis R, Rockett R, Basile K, Boucher YF, Pang V, Sessions O, Getchell M, Golubchik T, Lam C, Lin R. Advancing pathogen genomics in resource-limited settings. Cell Genomics. 2023 Dec 13;3(12).

[14] Ogunlaja A, Oginni O. Molecular epidemiology and phylodynamics of emerging and re-emerging viral infections: Implications for surveillance and control. Inter J Res Publicat Rev. 2022;6(2):2924-41.

[15] Christaki E. New technologies in predicting, preventing and controlling emerging infectious diseases. Virulence. 2015 Aug 18;6(6):558-65.

[16] Udegbe FC, Nwankwo EI, Igwama GT, Olaboye JA. Real-time data integration in diagnostic devices for predictive modeling of infectious disease outbreaks. Computer Science & IT Research Journal. 2023 Dec;4(3):525-45.

[17] Nwenekama Charles-Udeh. Leveraging financial innovation and stakeholder alignment to execute high-impact growth strategies across diverse market environments. Int J Res Finance Manage 2019;2(2):138-146. DOI: 10.33545/26175754.2019.v2.i2a.617

[18] Mukherjee R, Vidic J, Auger S, Wen HC, Pandey RP, Chang CM. Exploring disease management and control through pathogen diagnostics and one health initiative: A concise review. Antibiotics. 2023 Dec 23;13(1):17.

[19] Shaw LP, Sugden NC. Portable sequencing, genomic data, and scale in global emerging infectious disease surveillance. Geo: Geography and Environment. 2018 Jul;5(2):e00066.

[20] Espinoza B, Adiga A, Venkatramanan S, Warren AS, Chen J, Lewis BL, Vullikanti A, Swarup S, Moon S, Barrett CL, Athreya S. Coupled models of genomic surveillance and evolving pandemics with applications for timely public health interventions. Proceedings of the National Academy of Sciences. 2023 Nov 28;120(48):e2305227120.

[21] Deng X, den Bakker HC, Hendriksen RS. Genomic epidemiology: whole-genome-sequencing–powered surveillance and outbreak investigation of foodborne bacterial pathogens. Annual review of food science and technology. 2016 Feb 28;7(1):353-74.

[22] Ren H, Ling Y, Cao R, Wang Z, Li Y, Huang T. Early warning of emerging infectious diseases based on multimodal data. Biosafety and health. 2023 Aug 25;5(04):193-203.

[23] Halpin AL, McDonald LC, Elkins CA. Framing bacterial genomics for public health (care). Journal of clinical microbiology. 2021 Nov 18;59(12):10-128.

[24] Graham BS, Sullivan NJ. Emerging viral diseases from a vaccinology perspective: preparing for the next pandemic. Nature immunology. 2018 Jan;19(1):20-8.

[25] Bird BH, Mazet JA. Detection of emerging zoonotic pathogens: an integrated one health approach. Annual review of animal biosciences. 2018 Feb 15;6:121-39.

[26] Walker A, Houwaart T, Finzer P, Ehlkes L, Tyshaieva A, Damagnez M, Strelow D, Duplessis A, Nicolai J, Wienemann T, Tamayo T. Characterization of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection clusters based on integrated genomic surveillance, outbreak analysis and contact tracing in an urban setting. Clinical Infectious Diseases. 2022 Mar 15;74(6):1039-46.

[27] Hao R, Liu Y, Shen W, Zhao R, Jiang B, Song H, Yan M, Ma H. Surveillance of emerging infectious diseases for biosecurity. Science China Life Sciences. 2022 Aug;65(8):1504-16.

[28] World Health Organization. Future surveillance for epidemic and pandemic diseases: a 2023 perspective. World Health Organization; 2023 Dec 11.

[29] Sharan M, Vijay D, Yadav JP, Bedi JS, Dhaka P. Surveillance and response strategies for zoonotic diseases: a comprehensive review. Science in One Health. 2023 Jan 1;2:100050.

[30] Oeschger TM, McCloskey DS, Buchmann RM, Choubal AM, Boza JM, Mehta S, Erickson D. Early warning diagnostics for emerging infectious diseases in developing into late-stage pandemics. Accounts of Chemical Research. 2021 Sep 15;54(19):3656-66.

[31] Chiu KH, Sridhar S, Yuen KY. Preparation for the next pandemic: challenges in strengthening surveillance. Emerging Microbes & Infections. 2023 Dec 8;12(2):2240441.

[32] Nachega JB, Nsanzimana S, Rawat A, Wilson LA, Rosenthal PJ, Siedner MJ, Varma JK, Kilmarx PH, Mutesa L, Tanner M, Binagwaho A. Advancing detection and response capacities for emerging and re-emerging pathogens in Africa. The Lancet Infectious Diseases. 2023 May 1;23(5):e185-9.

[33] Folasole A. Data analytics and predictive modelling approaches for identifying emerging zoonotic infectious diseases: surveillance techniques, prediction accuracy, and public health implications. Int J Eng Technol Res Manag. 2023 Dec;7(12):292.

[34] Fasinu JO. Improving the health and safety of manufacturing workers by detecting and addressing personal protective equipment (PPE) violations in real-time with the use of automated PPE detection technology [thesis]. Morgantown (WV): West Virginia University; 2023. Available from: https://researchrepository.wvu.edu/etd/12222. doi: http://doi.org/10.33915/etd.12222

[35] Vashisht V, Vashisht A, Mondal AK, Farmaha J, Alptekin A, Singh H, Ahluwalia P, Srinivas A, Kolhe R. Genomics for emerging pathogen identification and monitoring: Prospects and obstacles. BioMedInformatics. 2023 Dec 7;3(4):1145-77.